These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 22353759

  • 1. Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
    McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, Demetrashvili MF, Miller AH, Musselman DL.
    Neuropsychopharmacology; 2012 May; 37(6):1444-54. PubMed ID: 22353759
    [Abstract] [Full Text] [Related]

  • 2. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
    Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH.
    Neuropsychopharmacology; 2002 May; 26(5):643-52. PubMed ID: 11927189
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
    Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P.
    J Affect Disord; 2007 Nov; 103(1-3):83-90. PubMed ID: 17292481
    [Abstract] [Full Text] [Related]

  • 4. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH.
    Aliment Pharmacol Ther; 2007 May 15; 25(10):1163-74. PubMed ID: 17451562
    [Abstract] [Full Text] [Related]

  • 5. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.
    Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH.
    Biol Psychiatry; 2003 Nov 01; 54(9):906-14. PubMed ID: 14573318
    [Abstract] [Full Text] [Related]

  • 6. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
    Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J, CTN194 Investigators.
    Contemp Clin Trials; 2008 Jul 01; 29(4):617-30. PubMed ID: 18262853
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J.
    J Clin Psychiatry; 2011 Apr 01; 72(4):522-8. PubMed ID: 21034680
    [Abstract] [Full Text] [Related]

  • 8. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T.
    Ann Intern Med; 2012 Jul 17; 157(2):94-103. PubMed ID: 22801672
    [Abstract] [Full Text] [Related]

  • 9. Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
    Raison CL, Demetrashvili M, Capuron L, Miller AH.
    CNS Drugs; 2005 Jul 17; 19(2):105-23. PubMed ID: 15697325
    [Abstract] [Full Text] [Related]

  • 10. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
    Maddock C, Baita A, Orrù MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM.
    J Psychopharmacol; 2004 Mar 17; 18(1):41-6. PubMed ID: 15107183
    [Abstract] [Full Text] [Related]

  • 11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 17; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 12. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S, Avasthi A, Grover S, Chawla YK.
    J Psychosom Res; 2014 Aug 17; 77(2):109-15. PubMed ID: 25077851
    [Abstract] [Full Text] [Related]

  • 13. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
    Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH.
    J Clin Psychiatry; 2005 Jan 17; 66(1):41-8. PubMed ID: 15669887
    [Abstract] [Full Text] [Related]

  • 14. Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy.
    Auyeung SF, Long Q, Royster EB, Murthy S, McNutt MD, Lawson D, Miller A, Manatunga A, Musselman DL.
    Clin Trials; 2009 Oct 17; 6(5):480-90. PubMed ID: 19786415
    [Abstract] [Full Text] [Related]

  • 15. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.
    Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M.
    Aliment Pharmacol Ther; 2002 Jun 17; 16(6):1091-9. PubMed ID: 12030950
    [Abstract] [Full Text] [Related]

  • 16. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F, Janssen G, Martin G, Lorenz R, Loeschke K, Soyka M, Folwaczny C, Schaefer M.
    Aliment Pharmacol Ther; 2009 Nov 15; 30(10):1049-59. PubMed ID: 19691667
    [Abstract] [Full Text] [Related]

  • 17. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
    Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Andrzej K.
    Psychiatr Pol; 2006 Nov 15; 40(4):799-808. PubMed ID: 17068951
    [Abstract] [Full Text] [Related]

  • 18. Paroxetine for the prevention of depression induced by high-dose interferon alfa.
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH.
    N Engl J Med; 2001 Mar 29; 344(13):961-6. PubMed ID: 11274622
    [Abstract] [Full Text] [Related]

  • 19. Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.
    Tomita T, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S, Nakamura K, Yasui-Furukori N.
    Clin Neuropharmacol; 2016 Mar 29; 39(3):135-9. PubMed ID: 27171569
    [Abstract] [Full Text] [Related]

  • 20. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M.
    Encephale; 2009 Oct 29; 35(5):477-83. PubMed ID: 19853722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.